[HTML][HTML] Trans-lesion synthesis and mismatch repair pathway crosstalk defines chemoresistance and hypermutation mechanisms in glioblastoma

X Cheng, J An, J Lou, Q Gu, W Ding, GN Droby… - Nature …, 2024 - nature.com
Almost all Glioblastoma (GBM) are either intrinsically resistant to the chemotherapeutical
drug temozolomide (TMZ) or acquire therapy-induced mutations that cause …

[PDF][PDF] Brain tumors on slice: A novel platform for personalized therapeutic screening

Y Sun, X Wang, G Ming, H Song - Cell Reports Medicine, 2023 - cell.com
Mann and Zhang et al. developed a robust ex vivo slice culture platform consisting of
resected patient high-and low-grade glioma tissue engrafted onto rat organotypic brain …

Auto-loaded TRAIL-exosomes derived from induced neural stem cells for brain cancer therapy

X Zhang, H Taylor, A Valdivia, R Dasari, A Buckley… - bioRxiv, 2024 - biorxiv.org
Transdifferentiation (TD), a somatic cell reprogramming process that eliminates pluripotent
intermediates, creates cells that are ideal for personalized anti-cancer therapy. Here, we …

A Novel ex-vivo platform for personalized treatment in metastatic ovarian cancer.

A Valdivia, RA Adefulajo, M Thang, LA Cuaboy, C John… - bioRxiv, 2024 - biorxiv.org
The lack of functional precision models that recapitulate the pathology and structure/function
relationship of advanced ovarian cancer (OC) within an appropriate anatomic setting …

Exploring molecular mechanisms involved in tumor rebound growth after MAPKi withdrawal in pLGG

D Kocher - 2024 - archiv.ub.uni-heidelberg.de
Pediatric low-grade gliomas (pLGGs) are the most common primary brain tumors in children
and are almost exclusively driven by alterations in the mitogen-activated protein kinase …